• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Catalent announces major China expansion with two new facilities

Catalent announces major China expansion with two new facilities

March 11, 2013
CenterWatch Staff

Catalent Pharma Solutions, a global drug development solutions provider, announced two joint ventures in China for its Softgel Technologies and Clinical Supply Solutions businesses. 

Catalent continues to expand its global leadership by providing access to drug delivery and clinical trial capabilities for customers in Asia Pacific. The company intends to make additional investments in these two facilities over the next several years to broaden its offerings in the Chinese market.

First, Catalent has agreed to acquire, pending regulatory approvals, a majority share in Haining-based, privately held Zhejiang Jiang Yuan Tang Biotechnology. The business produces nutritional softgel products for Chinese and Asia Pacific markets, and employs 120 staff.  Catalent intends to work with regulators for future expansion into OTC and prescription softgel manufacturing in China.

"The combination of Catalent's unparalleled track record of Softgel innovation and commercial success, and our deep understanding of the local market, will provide extensive benefits for our customers,” said Jiang Renfei, chairman and CEO of Zhejiang Jiang Yuan Tang Biotechnology.

In the second announcement, Catalent and ShangPharma, a China-based pharmaceutical and biotechnology R&D outsourcing company, have formed a joint-venture called Catalent (Shanghai) Clinical Trial Supplies.  A new 31,000 square foot facility in Shanghai, currently under construction, will be the first in China to provide end-to-end solutions for clinical trial supplies, including comparator sourcing, primary and secondary packaging and labeling, and storage and distribution.

"As part of our growth strategy, these initial steps enable us to better serve the important Chinese market for both global and domestic customers,” said John Chiminski, president and CEO of Catalent. “Our clients and their patients will benefit from access to Catalent's advanced technologies and solutions, together with best-in-class innovation, reliable supply and quality compliance."

Michael Hui, founder and CEO of ShangPharma, added, "We are delighted to be working with Catalent, a world leader in drug development services and clinical supply services. This cooperation will enable both ShangPharma and Catalent to better serve our multinational pharmaceutical customers through tailored, integrated solutions."

No other terms of the transactions have been disclosed.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing